OXFORD, England & TORONTO--(BUSINESS WIRE)--Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it ...

Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study Data ...

An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center ...

Bayesian network models predict urgent care visits in patients with non–small cell lung cancer receiving systemic therapy. The first model (left) integrates clinical and patient-reported outcome data, ...

Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...

Lung cancer remains the leading cause of cancer-related deaths worldwide, accounting for nearly one in five cancer deaths – around 1.8 million lives lost each year. One of the main reasons is late ...

Survival outcomes in non-small cell lung cancer: Real-world analysis of immunotherapy era vs pre-immunotherapy era, with insights into treatment settings, racial disparities, and socioeconomic impacts ...

New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...

MethylScan is a low-cost blood test that detects multiple cancers and liver diseases by analyzing DNA methylation patterns for affordable early detection.